|
LOC595101 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.61140000015858E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.04400000003435E-06 |
| Normal-vs-Stage2 |
2.55500000001518E-06 |
| Normal-vs-Stage3 |
3.41739999965007E-07 |
| Normal-vs-Stage4 |
6.18200002300284E-09 |
| Stage1-vs-Stage2 |
3.812000E-01 |
| Stage1-vs-Stage3 |
5.289200E-01 |
| Stage1-vs-Stage4 |
5.418200E-03 |
| Stage2-vs-Stage3 |
7.285200E-01 |
| Stage2-vs-Stage4 |
1.957800E-01 |
| Stage3-vs-Stage4 |
6.148000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.05939999947869E-07 |
| Normal-vs-AfricanAmerican |
2.830400E-02 |
| Normal-vs-Asian |
1.401660E-04 |
| Caucasian-vs-AfricanAmerican |
1.181990E-01 |
| Caucasian-vs-Asian |
4.238400E-01 |
| AfricanAmerican-vs-Asian |
3.736600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.91220000126336E-08 |
| Normal-vs-Female |
1.12370000004969E-06 |
| Male-vs-Female |
1.199980E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.73729999999317E-05 |
| Normal-vs-Age(41-60Yrs) |
3.0477000001472E-07 |
| Normal-vs-Age(61-80Yrs) |
7.90799999927927E-08 |
| Normal-vs-Age(81-100Yrs) |
1.056810E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.962180E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.016000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.952600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.121400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.138800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.551800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.458600E-01 |
| Classical-VS-Follicular |
5.123200E-01 |
| Classical-VS-Other |
9.764000E-01 |
| Classical-VS-Normal |
2.16949999998217E-06 |
| Tall-VS-Follicular |
8.848800E-01 |
| Tall-VS-Other |
8.116400E-01 |
| Tall-VS-Normal |
1.643690E-04 |
| Follicular-VS-Other |
8.676000E-01 |
| Follicular-VS-Normal |
7.76809999991634E-07 |
| Other-VS-Normal |
5.964000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.34119999994908E-07 |
| Normal-vs-N1 |
4.35819999999865E-05 |
| N0-vs-N1 |
5.756600E-01 |
|
|
